Monte Rosa Therapeutics announces Phase 1 data of MRT-8102

Monte Rosa Therapeutics (GLUE) announced positive interim data from an ongoing Phase 1 clinical study evaluating MRT-8102, a NEK7-directed MGD being developed for the treatment of inflammatory conditions driven by the NLRP3 inflammasome, IL-1, and IL-6. In subjects with elevated cardiovascular disease risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1/IL-6 driven inflammatory diseases, demonstrated durable reductions in systemic inflammation. After four weeks of MRT-8102 treatment, C-reactive protein levels were reduced by 85%, and 94% of study participants achieved CRP values below 2 mg/L, a threshold associated with reduced cardiovascular disease risk. Single ascending dose and multiple ascending dose cohorts demonstrated deep and sustained NEK7 degradation at doses from 5 mg to 400 mg. Favorable safety profile observed with mild to moderate adverse events and no evidence of increased infection risk. Ongoing GFORCE-1 Study of MRT-8102 in subjects with elevated CVD risk expanded to multiple dose levels to accelerate development in atherosclerotic cardiovascular disease; anticipated readout in H2 2026